Medivation to Host Conference Call to Discuss Top-Line 12-Month,Results From Dimebon Alzheimer's Disease Study ( eissComm Partners+1-415-946-1064 We...)

(Date:11/6/2009)... 6 Keryx Biopharmaceutic...call on Tuesday, November 10, 2009 at 8:30 a.m. ES...lts and business outlook for the remainder of 2009...pany, will host the call. Keryx will announce its...ase to be issued prior to the call. ,, In order...

(Date:11/6/2009)...6 Caraco Pharmaceutical ... ketorolac tromethamine ophthalmic solution, 0.5% ...ug Administration (FDA) for Sun Pharma,s Abbreviat...#174; opthalmic solution on the first day followin... therapeutically equivalent to Acular® Ophtha...

(Date:11/5/2009)..., Calif., Nov. 5 Transce...alty pharmaceutical company focused on the develop... that address important therapeutic needs in the f... a webcast and teleconference with management to d...rsday, November 12, 2009, at 5:00 p.m. Eastern Sta...

Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2 Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2 Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2 Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 13190 1 Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 13190 2 Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 13190 3 San Francisco Bay Area Affiliate of the Susan G Komen for the Cure Funds Over 241 2 Million This Year to Community Outreach Programs 52668 1 San Francisco Bay Area Affiliate of the Susan G Komen for the Cure Funds Over 241 2 Million This Year to Community Outreach Programs 52668 2 San Francisco Bay Area Affiliate of the Susan G Komen for the Cure Funds Over 241 2 Million This Year to Community Outreach Programs 52668 3 San Francisco Bay Area Affiliate of the Susan G Komen for the Cure Funds Over 241 2 Million This Year to Community Outreach Programs 52668 4 Babies Can Comprehend Canine Language 52664 1 Babies Can Comprehend Canine Language 52664 2

[0] Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST [0] Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution [0] Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12

.../ -- Sugammadex -,the novel selective relaxant bin...human healthcare business unit of Akzo Nobel -,dem...s faster,reversal of neuromuscular blockade as com...rative residual curarization (PORC) or,re-occurren...s,pivotal Aurora trial were presented today at the...

...7 - Geron,Corporation,s (Nasdaq:GERN) telomerase i...od pharmacokinetics and tolerability in,its ongoin...,lymphocytic leukemia (CLL), according to data pre...ompany,s president, oncology, at,the Pan Pacific L...rmacokinetics; Pharmacodynamics Consistent with,Ex...

Other Medicine Technology:Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 2 Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 3 Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 4 Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 2 Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 3 Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 4

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial

(Date:11/8/2009)...ssage of Health Care Reform Bill ,, Critical ...erage for all Americans ,, BALTIMORE, Nov. 7 /...nited States House of Representatives passed criti...ngthen Medicare for seniors and end discrimination...ericans out of affordable health coverage. ,, T...

(Date:11/7/2009)...Newswire-USNewswire/ -- Karen Ignagni, President a... released the following statement today on House p...support comprehensive health care reform, and we h...complete overhaul of how health insurance is provi...erage, elimination of pre-existing condition exclu...

(Date:11/7/2009)...wswire-USNewswire/ -- The American Medical Associa...ard for Citizenship and Community Service to Manus...IL. The award recognizes physicians who have gone ...o make an outstanding public service contribution ...ward today during the opening session of the 2009 ...

(Date:11/7/2009)...(CT), David A. Cook (GA), Louis J. Goodman (TX), P... ,, CHICAGO, Nov. 7 ...nted five medical society executive leaders with a...the goals and ideals of the medical profession. Th...olicy making meeting in Houston. ,, (Logo: h...

(Date:11/7/2009)...swire-USNewswire/ -- Members of the AMA are trying...solution rescinding the AMA,s support of HR 3962. ... responsible to their PATIENTS, not the leadership...icy for the Association of American Physicians and...other medical groups. ,, "If the AMA leadershi...

Breaking Medicine News(10 mins):Health News:AARP Maryland Key Vote News Alert 2 Health News:AARP Maryland Key Vote News Alert 3 Health News:AHIP Statement on House Passage of H.R. 3962 2 Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2 Health News:AMA Honors Medical Society Executives 2

[0] AARP Maryland Key Vote News Alert [0] AHIP Statement on House Passage of H.R. 3962 [0] AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members [0] AMA Honors Medical Society Executives [0] AMA Has Chance to Rescind Support of HR 3962; AMA Shout-Out from Public Urges Doctors to Answer to PATIENTS Not AMA Leadership

...m cells and their more committed kin, progenitor c...ability to produce different types of specialized ...r or replace damaged tissue holds great promise f...genitor cell? A team of researchers led by Berkele...

...., Feb. 27 Zimmer Holdings, Inc. (NYSE: ZMH ; S...utive Vice President and Chief Operating Officer o...d to its Board of Directors. Thermo Fisher Scient...are, and environmental, industrial and safety mark...

...rs note that exact in-flight medical emergency num...lthDay News) -- More than half of the medical emer...nting, a new study shows, but the researchers note...y data from 32 European airlines, although only fo...

...N, China, Feb. 27 /PRNewswire-Asia/ -- Winner Medi...Medical", the "Company"), a leading,manufacturer i...nd wound care,products), today announced that the ...by the patent: method for producing,spunlace non-w...

...h in Annual Net Sales Driven by Demand for Branded...m Operations, up 25% from 2007 , , - Provides 200..., CHADDS FORD, Pa., Feb. 27 Endo Pharmaceuticals ...ear ended December 31, 2008. , , Net sales for t...

..., ON, Feb. 27 /PRNewswire-FirstCall/ - Nuvo Resear...mpany focused on the research and development of d... skin using its topical and transdermal drug deliv...porate Developments:, - Presented positive Ph...

Cell microenvironments hold key to future stem cell therapies Zimmer Holdings Names Marc Casper to Board of Directors Fainting Most Common Medical Crisis on Planes Winner Medical Receives European Patent Office Approval for PurCotton(TM) Production Method Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results Nuvo announces 2008 fourth quarter and year-end financial results

Bateman Rongeur

Sundt Slim-Line Temporary Aneurysm Clip

Micro Needle Holders With Lock

Vascular Clamps B-3

Medicine Products:

Bateman Rongeur Sundt Slim-Line Temporary Aneurysm Clip Micro Needle Holders With Lock Vascular Clamps B-3

( eissComm Partners+1-415-946-1064 We...)Medivation to Host Conference Call to Discuss Top-Line 12-Month,Results From Dimebon Alzheimer's Disease Study,Health